Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs CYTK, ARWR, TECH: Buyback Yield % Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (MEX:BMRN) has a Buyback Yield % of 0.00 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioMarin Pharmaceutical and its competitors. According to the industry distribution chart, BioMarin Pharmaceutical ranks #999999 out of 742 companies in the Biotechnology industry.
Is BioMarin Pharmaceutical's Buyback Yield % too high?
BioMarin Pharmaceutical's current Buyback Yield % is 0.00. Based on the distribution chart, BioMarin Pharmaceutical ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Buyback Yield % compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #999999 out of 742 companies for Buyback Yield %. This places BioMarin Pharmaceutical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,507.58, compared to a current price of MXN959.00 — trading 36.4% below its estimated fair value. The current Buyback Yield % is 0.00. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 36.4% below its estimated GF Value™ of MXN1,507.58.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
Buyback Yield %: 0.00
GF Value™: MXN1,507.58 vs. price of MXN959.00 (36.4% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
